Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates Diabetic Nephropathy via suppressing SLC7A11-mediated ferroptosis [PDF]
卢 Yu +7 more
openalex +1 more source
The Effect of Potassium Canrenoate (Mineralocorticoid Receptor Antagonist) on the Markers of Inflammation in the Treatment of COVID-19 Pneumonia and Fibrosis—A Secondary Analysis of Randomized Placebo-Controlled Clinical Trial [PDF]
Igor Karolak +7 more
openalex +1 more source
Mineralocorticoid receptor antagonists and acute heart failure [PDF]
Carlos, Escobar, Luis, Manzano
openaire +2 more sources
The mineralocorticoid receptor antagonists spironolactone and eplerenone have become part of standard medical therapy for heart failure (HF). Randomized clinical trials have shown the clinical efficacy of spironolactone and eplerenone, which lead to ...
S N Tereshchenko +2 more
doaj
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure [PDF]
Javaid Iqbal +5 more
openalex +1 more source
Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist [PDF]
Luca Di Lullo +5 more
openalex +1 more source
Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]
Park JY, Jang Y, Hahn S.
europepmc +1 more source

